Skip to main content
CVSA logo

CVSA · Covista Inc.

Track CVSA — free
$119.81 +2.86 (+2.45%) At close · Nov 18
Market Cap
$3.98B
Shares
33.26M
Volume · Nov 18 297.94K Avg daily vol (3M) 378.63K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$119.81 Open$117.16 Day$117.07–121.33 52W close$89.36–140.98 Avg vol 30d403K Short int2.8M · 8.5% of shares · 8.2d Short vol57% Last earningsOct 29, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Jan 27, 2027 Est · unconfirmed · in 10 wks

Latest documents

2026
Nov 13
Current report 8-K/A Events of Jul 28
Shareholders approve equity plan and elect eleven directors

Covista Inc. shareholders approved the 2026 Equity Incentive Plan and elected eleven directors at the November 11, 2026 annual meeting. The board also assigned Emily Chiu and Leslie Storms to standing committees.

Director or officer change, or executive pay, Shareholder vote results
5 source passages
On November 11, 2026, Covista held its Annual Meeting of Shareholders (the “Annual Meeting”) virtually. Our shareholders elected the following eleven directors to serve until the 2027 Annual Meeting of Shareholders or until his or her successor has been duly elected and qualified. Approval of the Covista Inc. 2026 Equity Incentive Plan. Our shareholders approved this proposal. As previously disclosed, on July 28, 2026, the Board of Directors (the “Board”) of Covista Inc. (“Covista” or the “Company”) announced that it had appointed Emily Chiu and Leslie Storms as independent members of the Board, effective August 17, 2026. On November 11, 2026, the Board appointed Ms. Chiu to the Academic Quality and Audit and Finance Committees and Ms. Storms to the Compensation and External Relations Committees, effective immediately. Open the document at this passage
Oct 29
Earnings call
Revenue rose 10.7%, fiscal 2027 guidance raised

Covista reported fiscal 2027 first-quarter revenue of $511.5 million, up 10.7%, and adjusted EPS of $2.19, up 25.1%. Fiscal 2027 revenue guidance rose to $2,060,000,000 to $2,095,000,000, adjusted EPS guidance to $9 to $9.20, and CFO Bob Phelan announced his retirement.

6 source passages
first quarter revenue increased 10.7% to $511.5 million, with strong growth from all three segments. adjusted earnings per share was $2.19, up 25.1% compared with the prior year. raising both our revenue and adjusted earnings per share guidance for fiscal 2027. We now expect revenue in the range of $2,060,000,000 to $2,095,000,000, or approximately 5.5% to 7% growth year over year, up from our prior range of $2,050,000,000 to $2,090,000,000. We now expect adjusted earnings per share in the range of $9 to $9.20, or approximately 9% to 11.5% growth year-over-year, up from our prior range of $8.90 to $9.15. After nearly seven years at Covista and five as our CFO, I have decided to retire from Covista. Open the document at this passage
Oct 29
Quarterly report 10-Q FY2027 Q1, ended Sep 30
Covista first-quarter revenue rises 10.7% to $511.5 million

Covista's first-quarter fiscal 2027 revenue rose 10.7%, or $49.2 million, to $511.5 million, with net income up 9.0% to $67.4 million and diluted earnings per share up 16.8% to $1.95. Consolidated operating income increased 14.7% to $98.0 million, and the company repurchased 658,088 shares at an average cost of $127.63. Cash and cash equivalents fell to $222.2 million as of September 30, 2026 from $406.3 million at June 30, 2026.

Revenue $511.53M ▲ 10.7% Net income $67.43M ▲ 9.0% Diluted EPS $1.95 ▲ 16.8%
Read from the MD&A section
6 source passages
Covista revenue increased 10.7%, or $49.2 million, to $511.5 million in the first quarter of fiscal year 2027 compared to the prior year period driven by increased revenue across all segments. Net income increased 9.0%, or $5.6 million, to $67.4 million in the first quarter of fiscal year 2027 compared to the prior year period. Diluted earnings per share increased 16.8%, or $0.28, to $1.95, in the first quarter of fiscal year 2027 compared to the prior year period driven by the increase in net income and lower diluted shares due to share repurchases. Consolidated operating income increased 14.7%, or $12.6 million, to $98.0 million in the first quarter of fiscal year 2027 compared to the prior year period. Covista repurchased a total of 658,088 shares of its common stock under its share repurchase programs at an average cost of $127.63 per share during the first quarter of fiscal year 2027. Covista's consolidated cash and cash equivalents balance of $222.2 million and $406.3 million as of September 30, 2026 and June 30, 2026, respectively. Open the document at this passage
Oct 29
Current report 8-K
Revenue grows 10.7% as fiscal 2027 guidance rises

Covista Inc. reported first quarter fiscal year 2027 revenue of $511.5 million, up 10.7% year-over-year, and raised fiscal year 2027 revenue guidance to $2,060 million–$2,095 million and adjusted EPS guidance to $9.00–$9.20.

Financial results
4 source passages
Covista Inc. (NYSE: CVSA), America’s largest healthcare educator, today reported first quarter fiscal year 2027 results (ended Sep. 30, 2026). Revenue of $511.5 million, up 10.7% year-over-year Covista raised its revenue guidance for fiscal year 2027 from a range of $2,050 million to $2,090 million, or approximately 5% to 7% growth year-over-year, to a range of $2,060 million to $2,095 million, or approximately 5.5% to 7% growth year-over-year. Covista also raised its adjusted earnings per share guidance from a range of $8.90 to $9.15, or approximately 8% to 11% growth year-over-year, to a range of $9.00 to $9.20, or approximately 9% to 11.5% growth year-over-year. Open the document at this passage
Oct 14
Proxy statement DEFA14A
Proxy statement

Covista Inc. issued a supplement to its proxy statement clarifying that broker non-votes do not affect the vote on Proposal No. 4, the 2026 Equity Incentive Plan, and restating voting standards for the November 11, 2026 annual meeting.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.00B
Trailing 12 months
Net income (TTM)
$257.16M
Trailing 12 months
Revenue growth YoY
+10.7%
Year over year
Operating margin
19.8%
Trailing 12 months
P / E (TTM)
16.4
Trailing earnings · reciprocal yield 6.1%
FCF yield
8.9%
TTM · current market cap
Return on invested capital
18.1%
Trailing 12 months
Net cash
−$278.01M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-6.7%
Year over year · fewer shares
Price change (1Y)
+25.1%
Trailing year
Short interest
8.5%
Latest settlement · 8.2 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · May 7, 2026
Q3 FY26

TL;DR. Covista delivered 6.8% total enrollment growth to surpass 100,000 students, with Chamberlain returning to positive enrollment growth, and raised full-year FY26 revenue and adjusted EPS guidance on stronger momentum across segments.

Bullish
  • + Raised full-year FY2026 revenue guidance to $1,930M–$1,945M (8–9% growth) and adjusted EPS to $7.95–$8.15 (19–22% growth).
Bearish
  • − Consolidated adjusted EBITDA margin of 26.3% was down 110 bps YoY (and Walden adj. EBITDA margin fell from 30.3% to 26.7%), partly due to elevated strategic growth investments planned for Q4.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Excellent Quant / Vol High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −0%
below
Price vs 50-day avg −4%
below
RSI (14) 47
neutral
MACD trend Negative
52-week position 59%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −6%
trailing
6-month return +2%
trailing
YTD return +16%
this year
Relative strength +5%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $124 › 200d $120 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +54 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.47% of shares out · ▲ +1.4% MoM · 8.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
389 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Excellent
Revenue growth +9%
Y/Y
EPS growth +14%
Y/Y
Free cash flow $392.7M
Valuation P/E 16.4
in line
Buyback $577.8M
remaining
Balance sheet $256.5M
net debt
Quant / Vol
risk profile
High
Volatility 43%
annualized · 1-yr
Max drawdown −24%
past year
ATR 4.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 5
Latest guidance · from the 8-K filed Oct 29, 2026
Revenue guidance · fiscal year 2027 $2.06B – $2.1B
prior FY $1.95B midpoint +6.3% Y/Y
Previous outlook earlier release · from the 8-K filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Growth year-over-year · fiscal year 2027 5% – 7%
Prior guidance period ended · from the Earnings Call filed May 7, 2026
Revenue · full year $1.93B – $1.95B
Adjusted earnings per share · full year $7.95 – $8.15
Guided vs delivered · last 5 settled
Revenue full year
guided $1.93B – $1.95B
$1.95B Beat +0.9%
Revenue fiscal year 2024
guided $1.52B – $1.56B
$1.58B Beat +2.9%
Revenue fiscal year 2023
guided $1.4B – $1.45B
$1.45B Beat +1.8%
Expected earnings per share, diluted (GAAP) Year Ended June 30, 2023
guided $2.05 – $2.30
$2.05 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 6 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−0% Neutral
Price vs 50-day avg
−4% Neutral
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
59% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $124 › 200d $120 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +54 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.47% of shares out · ▲ +1.4% MoM · 8.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
389 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $89 Now $120 · 59% Range high $141
vs 200-day avg 0% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Free cash flow (non-GAAP) non-GAAP 355.17M Q1 FY27 —
Repurchased shares $84M Q1 FY 2027 —
Total enrollment 7.6% Q1 FY 2027 —
Adjusted EBITDA (non-GAAP) - Chamberlain non-GAAP $185.53M Year Ended June 30, 2026 —
Adjusted EBITDA (non-GAAP) - Medical and Veterinary non-GAAP $102.78M Year Ended June 30, 2026 —
Adjusted EBITDA (non-GAAP) - Walden non-GAAP $267.96M Year Ended June 30, 2026 —
Adjusted EBITDA - Home Office non-GAAP -$34.53M Year Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
Adjusted operating loss -$43.84M (non-GAAP)
+$658K Depreciation
+$8.66M Stock-based compensation
= Adjusted EBITDA - Home Office -$34.53M
Adjusted EBITDA margin non-GAAP 25.3% Q4 FY2026 —
Adjusted EBITDA margin (non-GAAP) non-GAAP 26.7% Year Ended June 30, 2026 —
Adjusted EBITDA margin (non-GAAP) - Chamberlain non-GAAP 24.7% Year Ended June 30, 2026 —
Adjusted EBITDA margin (non-GAAP) - Medical and Veterinary non-GAAP 25.8% Year Ended June 30, 2026 —
Adjusted EBITDA margin (non-GAAP) - Walden non-GAAP 33.3% Year Ended June 30, 2026 —
Adjusted operating loss non-GAAP -$43.84M fiscal year 2026 filing —
Average cost per share repurchased $98.35 fiscal year 2026 filing —
Average total student enrollment at Chamberlain 1.1% fiscal year 2026 filing —
Average total student enrollment at the medical and veterinary schools 4.5% fiscal year 2026 filing —
Average total student enrollment at Walden 13.2% fiscal year 2026 filing —
Chamberlain Total Students 39,501 Q4 FY2026 —
Medical and Veterinary enrolled approximately 5,250 students on average 5,250 FY2026 —
Medical and Veterinary Total Students 5,120 Q4 FY2026 —
Net debt (non-GAAP) non-GAAP $266.68M Year Ended June 30, 2026 —
Shares repurchased under share repurchase programs 2,421,920 fiscal year 2026 filing —
Walden Total Students 54,851 Q4 FY2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Education & Training Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CVSA
Covista Inc.
this stock
$3.98B +15.8% +9.3% 16.4 8.5%
EDU
New Oriental Education & Technology Group Inc.
$8.22B -3.6% +15.5% — 1.6%
TAL
TAL Education Group
$5.64B -6.8% +33.7% — 3.7%
LAUR
Laureate Education, Inc.
$4.57B -0.1% +19.5% 12.5 2.4%
LRN
Stride, Inc.
$3.27B +19.8% +3.3% 10.8 16.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
389
% held
102.6%
Net QoQ
-233.7K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
366
View
Short & Settlement
Short Interest Rising
Shares short
2.8M
Days to cover
8.2d
Change
+37.7K sh
View
Short Volume
Short vol %
57%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
2.3K
Value
$290.0K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
37.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.0B
Net income (FY)
$251.6M
EPS diluted
$7.04
View
Buybacks
Authorized
$750.0M
Remaining
$577.8M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K/A
Filed
Nov 13, 2026
This year
20

Covista Inc. shareholders approved the 2026 Equity Incentive Plan and elected eleven directors at the November 11, 2026 annual meeting. The board also assigned Emily Chiu and Leslie Storms to standing committees.

View
Proposed Sales
Value
$248.3K
Shares
1.8K
Filed
Aug 27, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
Covista Reports First Quarter Fis…
Published
Oct 29, 2026
View

Performance

5D 20D 120D MTD YTD
CVSA +0.2% -5.6% +1.7% -3.6% +15.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +4.1% -0.1% +5.2% -0.3% +8.7%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$750.00M
Spent (derived)
$172.20M
Remaining
$577.80M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 730464 CUSIP 00737L103 13F (30d) 392 filings 352 filers Visit website Investor relations